Reference
Chai, X., Hu, L., Zhang, Y., et al. (2020). Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. 02.03.931766. doi:10.1101/2020.02.03.931766
Chen, N., Zhou, M., Dong, X., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395(10223), 507-513. doi:10.1016/S0140-6736(20)30211-7.
Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARSCoV-2 therapeutics. Drug Development Research. 1–4.
Imai, Y., Kuba, K., Rao, S., et al. (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 436,112-116.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181(2),271-280.e8. doi:10.1016/j.cell.2020.02.052
Paz Ocaranza, M., Riquelme, J.A., García, L., et al. (2020). Counter-regulatory renin–angiotensin system in cardiovascular disease. Nature Reviews Cardiology. 17(2),116-129. doi:10.1038/s41569-019-0244-8.
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer, M.A., Solomon, S.D. (2020). Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.  New England Journal of Medicine. doi:10.1056/nejmsr2005760
Zhang, P., Zhu, L., Cai, J., et al. (2020). Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research. doi:10.1161/circresaha.120.317134
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov.bioRxiv . 2020:2020.01.26.919985. doi:10.1101/2020.01.26.919985
Zhou, P., Yang, X., Wang, X., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature .579,  270–273. doi:10.1038/s41586-020-2012-7.